Grundy, MD, PHD JAMA Cardiology US Preventive Services Task Force USPSTF Recommendation: Statins for Primary Prevention of Cardiovascular Disease in Adults US Preventive Services Task Force; Carol M. Mangione, MD, MSPH; Michael J. Barry, MD; Wanda K. Nicholson, MD, MPH, MBA; Michael Cabana, ...
Some countries have adopted lower thresholds, such as the American Heart Association (AHA) in its 2018 guidelines and the UK’s National Institute for Health and Care Excellence (NICE) in its 2023 update, both recommending statin therapy when the 10-year ASCVD risk reaches 7.5% [5, 6]. An...
Based on the UK-QRISK3 model, the 2014 UK-NICE guidelines use a 10-year ASCVD risk of 10% or greater to identify patients eligible for statin therapy (strong recommendation).6,16 The UK-NICE guidelines do not provide class II recommendations. Based on the European-SCORE1 model, the Europe...
High-intensity statin therapy should be initiated (Class I recommendation) if calculated 10-year ASCVD risk is ≥ 20% Moderate-intensity statin therapy should be initiated (Class I recommendation) if calculated 10-year ASCVD risk is ≥ 7.5% to <20%, and if risk assessment favors statin therapy...
The results are alarming: under the 2019 ESC guideline, 20% of the population received a class 1 recommendation for a statin, and under the 2021 guideline, this decreased to 4%. Including class II recommendations, the proportion of individuals recommended for a statin dropped from 56% to 19...
For patients with known or suspected statin intolerance and high ASCVD risk, non-statin therapy is currently a class IIa recommendation by the National Lipid Association (NLA).#Method:We accessed publicly available datasets from the Centers for Medicare and Medicaid Services (CMS). The non-statin ...
Statin vs no statin was associated with lower bleeding and MI risk; the bleeding and MI risk were proportional to ASCVD risk. For every 10,000 adults, aspirin reduced MI (very low risk: 3 events as monotherapy or 1 event with statin; very high risk: 49 events as monotherapy or 37 ...
we aimed to evaluate the cost-effectiveness of the ACC/AHA 2013 guidelines, which do not make a strong recommendation for CAC assessment,12 vs the 2018 guidelines, which recommend CAC assessment using a non-0 CAC score in African American individuals at intermediate risk for ASCVD, prevalence an...
Ten-year predicted ASCVD risk was calculated using the PCE and divided into the following risk strata: 5% to less than 7.5%, 7.5% to less than 20%, and 20% or greater based on the 2018 ACC/AHA guidelines recommendation for increased statin-derived benefit.1,4 Because the PCE does not ...
Therefore, the findings of this study have significant implications for public health as we continue to strive to decrease the risks of ASCVD—the number one cause of death in the US and worldwide.35,36 Acceptance of a statin therapy recommendation was found to be associated with achievement ...